DOCSLIB.ORG

2020 Annual Meeting Scientific Program Committee All Relationships Are Considered Compensated

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
2020 Annual Meeting Scientific Program Committee All Relationships Are Considered Compensated 2020 Annual Meeting Scientific Program Committee All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution Stock and Other Travel, (OPTIONAL) Consulting or Advisory Patents, Royalties, Other Expert Other Name Employment Leadership Ownership Honoraria Speakers' Bureau Research Funding Accommodations, Uncompensated Role Intellectual Property Testimony Relationship Interests Expenses Relationships Howard A. Burris III HCA Healthcare / HCA Healthcare / HCA Healthcare / AstraZeneca (Inst), Agios (Inst), Arch (Inst), Arvinas (Inst), Novartis Sarah Cannon Sarah Cannon Sarah Cannon Boehringer Ingelheim AstraZeneca (Inst), BioAtla (Inst), (Inst), Bristol-Myers BioMed Valley Discoveries (Inst), Squibb (Inst), Celgene Boehringer Ingelheim (Inst), Bristol- (Inst), Eisai (Inst), FORMA Myers Squibb (Inst), Celgene (Inst), Therapeutics (Inst), Incyte CicloMed (Inst), CytomX Therapeutics (Inst), Janssen (Inst), (Inst), eFFECTOR Therapeutics (Inst), MedImmune (Inst), Gilead Sciences (Inst), Mersana (Inst), Novartis GlaxoSmithKline (Inst), Harpoon (Inst), Roche/Genentech Therapeutics (Inst), Immunocore (Inst), (Inst), Tolero Incyte (Inst), Janssen (Inst), Jiangsu Pharmaceuticals (Inst) Hengrui Medicine (Inst), Jounce Therapeutics (Inst), Kyocera (Inst), Lilly (Inst), Loxo (Inst), Macrogenics (Inst), MedImmune (Inst), Merck (Inst), Millennium (Inst), Moderna Therapeutics (Inst), Novartis (Inst), Revolution Medicines (Inst), Roche/Genentech (Inst), Seattle Genetics (Inst), Takeda (Inst), Tesaro (Inst), TG Therapeutics (Inst), Verastem (Inst), Vertex (Inst) Suzanne George Abbott Laboratories, Bayer, Blueprint ARIAD (Inst), Bayer (Inst), Blueprint UptoDate Bayer Research to Abbvie (I), Allergan Medicines, Deciphera, Medicines (Inst), Deciphera (Inst), Practice (I) Lilly, MORE Health, Novartis (Inst), Pfizer (Inst) Research to Practice, UpToDate Norah L. Henry Abbvie (Inst), Innocrin Pharma (Inst), Pfizer (Inst) Melissa L. Johnson Araxes Pharma (Inst), Abbvie (Inst), Acerta Pharma (Inst), Abbvie, Astellas Pharma, Astellas Pharma (I), Adaptimmune (Inst), Amgen (Inst), AstraZeneca, Boehringer AstraZeneca (Inst), Array BioPharma (Inst), AstraZeneca Ingelheim, Bristol-Myers BeiGene (Inst), Boehringer (Inst), BeiGene (Inst), BerGenBio Squibb, Clovis Oncology, Ingelheim (Inst), Bristol- (Inst), Birdie (Inst), Boehringer Daiichi Sankyo, EMD Myers Squibb (Inst), Ingelheim (Inst), Bristol-Myers Squibb Serono, Exelixis, Calithera Biosciences (Inst), Checkpoint Therapeutics (Inst), Genentech, Incyte, (Inst), Celgene (Inst), Clovis Oncology (Inst), Corvus Merck, Pfizer, Sysmex, Genentech/Roche (Inst), Pharmaceuticals (Inst), CytomX Vapotherm Guardant Health (Inst), Therapeutics (Inst), Daiichi Sankyo Incyte (Inst), Loxo (Inst), (Inst), Dynavax (Inst), EMD Serono Merck (Inst), Mersana (Inst), Foundation Medicine (Inst), G1 (Inst), Mirati Therapeutics Therapeutics (Inst), Genentech/Roche (Inst), Otsuka (I), Pfizer (Inst), Genmab (Inst), Genocea (Inst), Ribon Therapeutics Biosciences (Inst), GlaxoSmithKline (Inst), Sanofi (Inst) (Inst), Gritstone Oncology (Inst), Guardant Health (Inst), Hengrui Pharmaceutical (Inst), Incyte (Inst), Janssen (Inst), Kadmon (Inst), Lilly (Inst), Loxo (Inst), Lycera (Inst), Merck (Inst), Mersana (Inst), Mirati Therapeutics (Inst), Neovia Oncology (Inst), Novartis (Inst), OncoMed (Inst), Pfizer (Inst), Regeneron (Inst), Sanofi (Inst), Shattuck Labs (Inst), Stem CentRx (Inst), Syndax (Inst), Takeda (Inst), Tarveda Therapeutics (Inst) Biostatistics Karla V. Ballman Agenus, ARIAD, Prostate cancer signature Janssen Medtronic, Takeda patent (Inst), Immune Oncology, Lilly enrichment signature for response to trastuzumab in HER2+ breast cancer (Inst) Thomas Braun Johnson & OncoImmune Johnson (I) Suzanne E. AstraZeneca Patent pending for a statistical Dahlberg model assessing tumor growth (Inst) Rosemarie Mick Editas Medicine Infiniti Medical Mary W. Redman Ignyta Yu Shyr Aduro Biotech, Royalty for TNBCType for GlaxoSmithKline, Janssen Insight Genetics. TNBCType Research & Development, is a web-based subtyping tool Novartis, Pfizer, TNBCtype for candidate Roche/Genentech TNBC samples using our gene expression meta data and classification method. Nolan Wages Abbvie (Inst) Breast Cancer - Metastatic Adam Brufsky Agendia, Bayer, Bioarray Therapeutics, BioTheranostics, Celgene, Eisai, Genentech/Roche, Genomic Health, Lilly, Merck, Myriad Pharmaceuticals, NanoString Technologies, Novartis, Pfizer, Puma Biotechnology Roisin M. Connolly Genentech/Roche (Inst), Macrogenics Genentech/Roche, (Inst), Merck (Inst), Merrimack (Inst), Syndax Novartis (Inst), Puma Biotechnology (Inst) Olwen M. Hahn Via Oncology Cardinal Health (I) Pfizer Cardinal Health (I) Erika P. Hamilton Boehringer Ingelheim Abbvie (Inst), Acerta Pharma (Inst), Amgen, AstraZeneca, (Inst), Cascadian ArQule (Inst), AstraZeneca (Inst), Bayer, Bristol-Myers Therapeutics (Inst), Daiichi BerGenBio (Inst), Boehringer Squibb, Clovis Oncology, Sankyo (Inst), Eisai (Inst), Ingelheim (Inst), Cascadian Eisai, EMD Serono, Genentech/Roche (Inst), Therapeutics (Inst), Clovis Oncology Foundation Medicine, Lilly (Inst), Mersana (Inst), (Inst), Curis (Inst), CytomX Genentech, Pfizer (Inst), Puma Therapeutics (Inst), Daiichi Sankyo Genentech/Roche, Biotechnology (Inst) (Inst), Deciphera (Inst), eFFECTOR Genzyme, Guardant Therapeutics (Inst), Eisai (Inst), EMD Health, Helsinn Serono (Inst), Fujifilm (Inst), Therapeutics, HERON, Genentech/Roche (Inst), H3 Lexicon, Lilly, Medivation, Biomedicine (Inst), Hutchison Merck, Novartis, Pfizer, MediPharma (Inst), Immunomedics Roche, Sysmex, Tesaro (Inst), InventisBio (Inst), Kadmon (Inst), Leap Therapeutics (Inst), Lilly (Inst), Lycera (Inst), Macrogenics (Inst), Mallinckrodt (Inst), MedImmune (Inst), Medivation (Inst), Mersana (Inst), Merus (Inst), Millennium (Inst), Novartis (Inst), Nucana (Inst), OncoMed (Inst), Oncothyreon (Inst), Pfizer (Inst), PharmaMar (Inst), Radius Health (Inst), Regeneron (Inst), Rgenix (Inst), Stem CentRx (Inst), Syndax (Inst), Syros Pharmaceuticals (Inst), Taiho Pharmaceutical (Inst), Takeda (Inst), TapImmune (Inst), Tesaro (Inst), TetraLogic Pharmaceuticals (Inst), Verastem (Inst), Zymeworks (Inst) Elizabeth C. Reed Pfizer Pfizer/NCCN Nicholas C. Turner AstraZeneca, Bicycle AstraZeneca (Inst), Bio-Rad (Inst), Therapeutics, Bristol- Clovis Oncology (Inst), Guardant Myers Squibb, Lilly, Merck Health (Inst), Pfizer (Inst), Roche (Inst) Sharp & Dohme, Novartis, Pfizer, Roche, Tesaro Breast Cancer -Local/Regional/Adjuvant Lior Z. Braunstein Naamit K. Gerber OncLive Eun-Sil S. Hwang Henry M. Kuerer Cardinal Health, Genomic PER Genomic Health (Inst) NEJM Group, McGraw-Hill Health, Targeted Medical Publishing Education Erica L. Mayer Context Therapeutics, Myriad Genetics (Inst), Pfizer (Inst) Eisai, Lilly, Novartis, Pfizer Vered Stearns Iridium Therapeutics Abbvie, Biocept, MedImmune, Immunomedics Novartis, Pfizer, Puma Biotechnology Richard C. Zellars Cancer Prevention, Risk Reduction, and Genetics John R. Goffin Amgen, Boehringer AstraZeneca Ingelheim, Bristol-Myers Squibb, Merck Erin W. Hofstatter UpToDate Andrew McKenzie Mark E. Robson AstraZeneca AstraZeneca, McKesson Abbvie (Inst), AstraZeneca (Inst), AstraZeneca, Pfizer Clinical Care Daiichi Sankyo, Merck, InVitae (Inst), Medivation (Inst), Myriad Options, Physician Pfizer Genetics (Inst), Tesaro (Inst) Education Resource, Research to Practice Nadine M. Tung AstraZeneca Care Delivery and Regulatory Policy Adam P. Dicker American Society Oncohost Apex, Celldex, Cybrexa Prostate Cancer Foundation We recently filed a patient: Wilson, Socini EMD Serono, Ferring, Dreamit Ventures Google for Radiation Therapeutics, EMD "doped beo compounds for Merck, Self Care Catalyst Oncology, Serono, Janssen, Johnson optically stimulated Department of & Johnson, Oncohost, luminescence (OSL) and Defense-Prostate Roche, Self Care Catalyst, thermoluminescence (TL) Cancer Research Thirdbridge radiation dosimetry" Program, NRG Oncology Lynn J. Howie Ipsen National Breast Cancer Coalition Richard T. Lee Tracon (Inst) Grow Ohio Pharmaceuticals Enrique Soto Perez Roche (I) De Celis Ari Vanderwalde Bristol-Myers Squibb, Amgen (Inst), Merck (Inst), Genentech/Roche, Caris Genentech/Roche (Inst), Millennium Life Sciences, Compugen, (Inst), AstraZeneca (Inst), Polynoma Immunocore, Concerto (Inst), Lilly (Inst), Bristol-Myers Squibb Health-AI, Elsevier (Inst), Amgen (Inst), Replimune (Inst), Caris Life Sciences (Inst), EMD Serono (Inst) Central Nervous System Tumors E. Antonio Chiocca DNAtrix Merck Advantagene, Alcyone Amgen Patents related to oncolytic Lifesciences, DNAtrix, virus technology, gene Insigthec, NanoTX, therapy, microRNA, exosome, Oncorus, Sigilon, antibodies StemGen, Tocagen, ZIOPHARM Oncology Timothy F. Notable Labs Abbvie, Agios, Alexion U.S. Provisional Application Global Coalition for Cloughesy Pharmaceuticals, Bayer, No.: 62/819,322 Adaptive Research Boehringer Ingelheim, Title: COMPOSITIONS AND 501(c)(3) Boston Biomedical, Bristol- METHODS FOR TREATING Myers Squibb, Celgene, CANCER Cortice, Deciphera, DelMar Filing Date: March 15, 2019 Pharmaceuticals, Genocea Inventor(s): David A. Biosciences, GW Nathanson et al. Pharmaceuticals, Human FH Reference No.: UCH- Longevity, Insys 17760 (32246-17760) Therapeutics, KIYATEC, Your Reference No.: [UCLA Lilly, Merck, NewGen 2019-630-1] US Therapeutics, Notable Labs, Novartis, Novocure, Novogen, Oxigene, Pfizer, Puma Biotechnology, Roche/Genentech, Sunovion, Tocagen,
Load more

Recommended publications
  • Manufacturers and Wholesalers Street
    Nevada AB128 Code of Conduct Compliant Companies Manufacturers and Wholesalers Street City ST Zip 10 Edison Street LLC 13 Edison Street LLC Abbott Diabetes Care Division Abbott Diagnostic Division Abbott Electrophysiology (including Kalila Medical 2- 2016)) Abbott Laboratories 100 Abbott Park Road, Dept. EC10, Bldg. APGA-2 Abbott Park IL 60064 Abbott Medical Optics Abbott Molecular Division Abbott Nutrition Products Division Abbott Vascular Division (includes Tendyne 9-2015) AbbVie, Inc. 1 N. Waukegan Road North Chicago IL 60064 Acadia Phamaceuticals 3611 Valley Centre Drive, Suite 300 San Diego CA 92130 Accelero Health Partners, LLC Acclarent, Inc. 1525-B O'Brien Dr. Menlo Park CA 94025 Accuri Cyometers, Inc. Ace Surgical Supply, Inc. 1034 Pearl St. Brockton MA 02301 Acorda Therapeutics, Inc. 420 Sawmill River Road Ardsley NY 10532 AcriVet, Inc. Actavis W.C. Holding, Inc. Morris Corporate Center III, 400 Interpace Parkway Parsippany NJ 07054 Actavis , Inc. Actelion Pharmaceuticals US, Inc. 5000 Shoreline Court, Suite 200 S. San Francisco CA 94080 Activis 400 Interpace parkway Parsippany NJ 07054 A-Dec, Inc. 2601 Crestview Dr. Newberg OR 97132 Advanced Respiratory, Inc. Advanced Sterilization Products 33 Technology Drive Irvine CA 92618 Advanced Vision Research, Inc., dba Akorn Consumer Health Aegerion Pharmaceuticals, Inc. 101 Main Street, Suite 1850 Cambridge MA 02142 Aesculap Implant Systems, Inc. Aesculap, Inc. 3773 Corporate Parkway Center Valley PA 18034 Aesthera Corporation Afaxys, Inc. PO Box 20158 Charleston SC 29413 AGMS, Inc. Akorn (New Jersey) Inc. Page 1 of 23 Pages 2/15/2017 Nevada AB128 Code of Conduct Compliant Companies Akorn AG (formerly Excelvision AG) Akorn Animal Health, Inc.
    [Show full text]
  • Biocentury 8.15.16
    WEEK OF AUGUST 15, 2016 6 PRODUCT DEVELOPMENT: NO ANTIGEN LEFT BEHIND Amgen has added to its immuno-oncology arsenal with its deal for Advaxis’ pan- epitope neoantigen vaccine platform. SERVING RETURNS 9 EMERGING COMPANY PROFILE: RESTRAINING TRANSLATION BY STEVE EDELSON, SENIOR EDITOR Bantam is developing small molecule eIF4E inhibitors to treat a range of cancers, China’s Ally Bridge Group hit the investment world’s starting with B cell malignancies. radar in 2015 with its audacious move to take CRO WuXi PharmaTech Inc. private. If the firm and its partners can engineer the first fruits of that move with REGULATION: the listing of WuXi’s biologics unit in Hong Kong this 10 year, the question is what will be its next moves to ADAPTING FOR THE REAL WORLD generate outsized returns for its investors. EMA says better strategies for real-world evidence and more patient and payer involvement are necessary Ally Bridge, which has a about $1.5 billion under next steps for its adaptive pathway initiative. management across three funds and an international base of LPs, thinks its returns and continued visibility will come from a handful of public and private portfolio companies with transformative data events, the first of EBB & FLOW: 13 which should come this half. LION’S SHARE OF THE WORK Aslan’s validating event. Plus: Cutting a check The firm also says it is working on new private equity to Cleave; and Ironwood’s operating leverage. deals that will rival WuXi in terms of size and impact. Ally Bridge is keeping its private equity plans under wraps, and does not disclose names of investments in its Asia hedge fund.
    [Show full text]
  • 2020-2021 Cancer Communications Committee Disclosures All Relationships Are Considered Compensated
    2020-2021 Cancer Communications Committee Disclosures All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution Name EMAIL Committee Employment Leadership Stock and Other Honoraria Consulting or Advisory Speakers' Bureau Research Funding Patents, Royalties, Other Expert Testimony Travel, Other Relationship (OPTIONAL) (OPTIONAL) Open Member Status Ownership Interests Role Intellectual Property Accommodations, Uncompensated Payments Link Expenses Relationships Neeraj Agarwal [email protected] Active Astellas Pharma Active Biotech (Inst) Astellas Pharma Amgen (Inst) AstraZeneca AstraZeneca (Inst) AstraZeneca Bavarian Nordic (Inst) AVEO Bayer (Inst) Bayer BN ImmunoTherapeutics Bristol-Myers Squibb (Inst) Calithera Biosciences Bristol-Myers Squibb (Inst) Eisai Calithera Biosciences EMD Serono (Inst) Exelixis Celldex (Inst) Foundation Medicine Eisai (Inst) Foundation One Inc Exelixis (Inst) Genentech Genentech (Inst) Janssen Oncology GlaxoSmithKline (Inst) Lilly Immunomedics (Inst) Lilly Janssen (Inst) lily Merck (Inst) Medivation/Astellas Newlink Genetics (Inst) MEI Pharma Novartis (Inst) Merck Pfizer (Inst) Nektar Prometheus (Inst) Novartis Rexahn Pharmaceuticals Pfizer (Inst) Pfizer Sanofi (Inst) Pharmacyclics Takeda (Inst) Seattle Genetics TRACON Pharma (Inst) Muhammad S. Beg muhammad.beg@utsouthwestern. Active Array BioPharma Agios (Inst) edu AstraZeneca/MedImmune ArQule (Inst) Cancer Commons AstraZeneca/MedImmune Ipsen (Inst) Legend Biotech
    [Show full text]
  • Spectrum Pharmaceuticals Inc
    SPECTRUM PHARMACEUTICALS INC FORM 10-K (Annual Report) Filed 03/12/14 for the Period Ending 12/31/13 Address 11500 S. EASTERN AVE., SUITE 240 HENDERSON, NV 89052 Telephone 702-835-6300 CIK 0000831547 Symbol SPPI SIC Code 2834 - Pharmaceutical Preparations Industry Biotechnology & Drugs Sector Healthcare Fiscal Year 12/31 http://www.edgar-online.com © Copyright 2014, EDGAR Online, Inc. All Rights Reserved. Distribution and use of this document restricted under EDGAR Online, Inc. Terms of Use. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2013 TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-35006 SPECTRUM PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 93 -0979187 (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification No.) 11500 South Eastern Avenue, Suite 240 Henderson, Nevada 89052 (Address of principal executive offices) (702) 835-6300 (Registrant’s telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: Title of Each Class Name of Each Exchange on Which Registered Common Stock, $0.001 par value The NASDAQ Stock Market, LLC Rights to Purchase Series B Junior Participating Preferred Stock Securities registered pursuant to Section 12(g) of the Act: None Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.
    [Show full text]
  • 2019 Breakthrough Summit Co-Host Committee 2019 Breakthrough
    2019 Breakthrough Summit Co-Host Committee All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution Stock and Other Patents, Royalties, Travel, Speakers' Expert Name Employment Leadership Ownership Honoraria Consulting or Advisory Role Research Funding Other Intellectual Accommodations, Other Bureau Testimony Interests Property Expenses Dae Ho Lee Abbvie, AstraZeneca/MedImmune, Boehringer ST Cube Ingelheim, Bristol-Myers Squibb, Chong Kun Dang Pharmaceutical, CJ Healthcare, Janssen, Lilly, Merck, MSD, Mundipharma, Novartis, Ono Pharmaceutical, Pfizer, Roche/Genentech, Samyang, ST Cube, Takeda Ekaphop Amgen, AstraZeneca, Boehringer Ingelheim, Bristol- AstraZeneca, MSD, Sirachainan Myers Squibb, Diethelm Keller Logistics, LF Asia, Pfizer Merck, MSD, Mundipharma, Roche, Sanofi/Aventis Lillian L. Siu Agios (I) Agios (I) AstraZeneca/MedImmune, Loxo, Merck, Amgen (Inst), Astellas Pharma (Inst), AstraZeneca (Inst), Bayer (Inst), MorphoSys, Roche, Symphony Evolution Boehringer Ingelheim (Inst), Bristol-Myers Squibb (Inst), Genentech/Roche (Inst), GlaxoSmithKline (Inst), MedImmune (Inst), Merck (Inst), Novartis (Inst), Pfizer (Inst), Symphony Evolution (Inst) Virote Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Amgen, AstraZeneca, Boehringer Ingelheim, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eisai, Lilly, Amgen, AstraZeneca, Sriuranpong Bristol-Myers Squibb, Eisai, Lilly, MSD Oncology, Eisai, MSD Oncology, Novartis, Roche MSD Oncology,
    [Show full text]
  • Based on Our Discussion with Radford, Management Identified Our Peer Companies to Include the Following 19 Biotechnology and Pharmaceutical Companies for 2015
    Based on our discussion with Radford, management identified our peer companies to include the following 19 biotechnology and pharmaceutical companies for 2015: Ariad Pharmaceuticals Inc. Infinity Pharmaceuticals, Inc. Progenics Pharmaceuticals, Inc. Array BiopPharma, Inc. Lexicon Pharmaceuticals, Inc Repligen Corporation Celldex Therapeutics, Inc. MacroGenics, Inc. Spectrum Pharmaceuticals, Inc. CTI BioPharma Corp. Merrimack Pharmaceuticals, Inc. Synta Pharmaceuticals Corp. DepoMed Inc. NewLink Genetics Corporation XOMA Corporation Halozyme Therpeutics, Inc. OncoMed Pharmaceuticals, Inc. Immunomedics Inc. Peregrine Pharmaceuticals, Inc These peer companies were selected from among publicly-held U.S. pharmaceutical and biotechnology companies with comparable operations in mid– to late–stages of product development or small commercial products in the U.S. based on the following criteria: number and stage of development programs; number of employees; market capitalization; and number of and revenue from commercial products. The market data included information as to base salaries, cash bonuses and stock option awards. Use of Compensation Consultants Our Compensation Committee is authorized to retain its own independent advisors to assist in carrying out its responsibilities. Our Compensation Committee engaged Radford to analyze historic compensation and establish recommendations for executive compensation for 2015 and methodologies for determining compensation on an on-going basis. Benchmarking in the Context of Our Other Executive Compensation Principles Our Compensation Committee and our Board of Directors use market data as one means of evaluating and establishing executive pay. In instances where an executive officer is believed to be especially suited to our company or important to our success, the Compensation Committee may establish or recommend compensation that deviates from industry averages or other specific benchmarks.
    [Show full text]
  • JMP Securities Healthcare Conference to Be Held in New York
    JMP Securities Healthcare Conference to Be Held in New York SAN FRANCISCO, Oct 01, 2008 (BUSINESS WIRE) -- JMP Group Inc. (NYSE:JMP), an investment banking and alternative asset management firm, announced today that its broker-dealer subsidiary, JMPSecurities, will host the third annual JMP Securities Healthcare Focus Conference at Le Parker Meridien in New York on Monday and Tuesday, October 6 and 7, 2008. The two-day conference will feature presentations by senior executives of nearly 90 public and private companies in the biotechnology, medical devices and healthcare services industries before an audience of institutional investors and financial sponsors. For additional details or to register to attend the event, visit www.jmpsecurities.com/about/events.html or www.twstevent.com/jmp.html. Companies scheduled to present as of September 30, 2008; subject to change: A.D.A.M., Inc. ACADIA Pharmaceuticals Inc. Acceleron Pharma, Inc. Achillion Pharmaceuticals, Inc. Alexza Pharmaceuticals, Inc. Allos Therapeutics, Inc. Allscripts Healthcare Solutions, Inc. Alnylam Pharmaceuticals, Inc. American CareSource Holdings, Inc. Anadys Pharmaceuticals, Inc. ARCA biopharma, Inc. Ardea Biosciences, Inc. athenahealth Inc. AtriCure, Inc. AVEO Pharmaceuticals, Inc. AVI BioPharma, Inc. BioCryst Pharmaceuticals, Inc. C. R. Bard, Inc. Cadence Pharmaceuticals, Inc. Celera Corporation Celgene Corporation Celleration, Inc. Cerus Corporation Chem Rx Corporation Concert Pharmaceuticals, Inc. Corcept Therapeutics Incorporated Cypress Bioscience, Inc. Cytokinetics, Incorporated DexCom, Inc. DiagnoCure Inc. Dialysis Corporation of America Echo Therapeutics, Inc. Eclipsys Corp. Enanta Pharmaceuticals, Inc. Endocare Inc. Exelixis, Inc. EyeGate Pharmaceuticals, Inc. Genomic Health, Inc. Given Imaging, Ltd. HeartWare Limited Horizon Therapeutics, Inc. Human Genome Sciences, Inc. HydroCision, Inc. Idenix Pharmaceuticals, Inc. Idera Pharmaceuticals, Inc.
    [Show full text]
  • Company Description
    November 8, 2017 Laura S. Engel, CPA [email protected] 214-987-4121 MARKET STATISTICS COMPANY DESCRIPTION Exchange / Symbol NasdaqGS: SPPI Spectrum Pharmaceuticals, Inc. is focused on the acquisition, development and Price: $19.00 commercialization of proprietary drugs, primarily addressing the oncology/hematology Market Cap ($mm): $1,912.6 markets. Spectrum's business strategy involves in-licensing or acquiring diversified drugs Enterprise Value ($mm): $1,766.6 as well as creating an expanding pipeline of prospective candidates in late-stage Phase 2 and Phase 3 clinical trials. Over the years, the Company has developed comprehensive in- Shares Outstanding (mm): 100.7 house clinical development/regulatory capabilities, along with an extensive commercial Float: 85% network, including a direct sales force in the U.S. and distributors in Europe and Japan Volume (3-month avg., mm): 1.8 for its marketed products. Spectrum’s diverse portfolio consists of six marketed oncology drugs and a pipeline with three advanced stage products that address sizable markets. 52-week Range: $3.73 – $21.95 Spectrum Pharmaceuticals is headquartered in Henderson, Nevada, and as last reported, Industry: Biotechnology the Company had 227 employees. CONDENSED BALANCE SHEET ($mm, except per share data) Balance Sheet Date 9/30/2017 SUMMARY Cash & Cash Equivalents: $247.7 Over the last several quarters, Spectrum’s primary focus has shifted beyond its Cash/Share: $2.46 established portfolio of niche cancer drugs to opportunities for its newer drugs, with three in its late-stage pipeline (Poziotinib, Rolontis™, and Qapzola®), and all of which Debt: $101.8 have meaningful competitive advantages and address indications with significant Equity (Book Value): $304.7 populations.
    [Show full text]
  • 13-ICML Abbvie Acerta Pharma Amgen (Europe) Gmbh Bayer
    13th INTERNATIONAL CONFERENCE ON MALIGNANT LYMPHOMA Lugano, Switzerland, June 17-20, 2015 13-ICML THE CONFERENCE ORGANIZERS WISH TO THANK THE FOLLOWING SPONSORS FOR THEIR UNRESTRICTED FINANCIAL SUPPORT: Abbvie Acerta Pharma Amgen (Europe) GmbH Bayer HealthCare Pharmaceuticals, Inc. Bristol-Myers Squibb Celgene Corporation CTI Life Sciences Ltd. F. Hoffmann-La Roche Ltd . www.roche.com Gilead Sciences, Inc. Gilead Sciences Europe Ltd. Infinity Pharmaceuticals, Inc. Institut Biochimique SA – IBSA Janssen Pharmaceutical Companies of Johnson & Johnson Medicom Worldwide, Inc. Mentrik Biotech, LLC Mundipharma Oncology www.mundipharma.ch Novartis Oncology Pfizer Oncology Seattle Genetics, Inc. Servier sigma-tau Research Switzerland SA Spectrum Pharmaceuticals, Inc. Takeda Oncology Vifor SA THE CONFERENCE ORGANIZERS WISH TO THANK THE FOLLOWING CONTRIBUTORS FOR THEIR SUPPORT : American Association for Cancer Research – AACR Arcobaleno - Comunità Tariffale Ticino e Moesano CALYM, the Carnot Lymphoma Institute City of Lugano www.lugano.ch/ European School of Oncology – ESO www.eso.net European Society for Medical www.esmo.org Oncology – ESMO European Society for Radiotherapy and Oncology – ESTRO Hotel Splendide Royal www.splendide.ch International Extranodal Lymphoma Study Group - IELSG International Lymphoma Radiation Oncology Group - ILROG Kompetenznetz Maligne Lymphome e.V. – KML www.LHRM.de Leukämiehilfe Rhein-Main g.e.V. - LHRM Lugano MICE Convention Bureau www.luganomice.ch Lugano University Campus http://www.lymphomahub.co Lymphoma HUB m/search/ICML%25202015 Omega SA Repubblica e Cantone Ticino/Fondo Swisslos San Salvatore Foundation Schweizerische Patientenorganisation für Lymphombetroffene und Angehörige - ho / noho Swiss Cancer League Swiss Cancer Research Foundation Swiss International Air Lines The Leukemia Lymphoma Society Ticino Tourism www.ticino.ch .
    [Show full text]
  • IHE Ishares US Pharmaceuticals ETF Gray Swan Event Factor For
    ETF Risk Report: IHE Buyer beware: Every ETF holds the full risk of its underlying equities Disclosures in the best interest of investors iShares US Pharmaceuticals ETF Gray Swan Event Risks exist for every equity held by IHE. Gray swan events include accounting fraud, management failures, failed internal controls, M&A problems, restatements, etc. These risks occur infrequently, but Gray Swan Event Factor for IHE 2.72% consistently for all equities. Equities account for 99.86% of IHE’s assets. Most investors ignore these risks until after they are disclosed; whereupon a stock’s price drops precipitously. Just as insurance companies can predict likely costs for a driver’s future car accidents based on the driver’s history, Watchdog Research contacts each ETF asking how they notify investors about we predict the likely cost (price drop) for IHE following accounting governance risks in equities in their fund. We will publish their response gray swan disclosures within its holdings. The expected when received. price decrease across the IHE equity portfolio is 2.72%. However, individual equity risks vary signicantly. This report helps investors know their risk exposure. Inception Date: 05/01/2020 Year-to-Date Return: -0.64% The iShares U.S. Pharmaceuticals ETF tracks the investment results of the Dow Jones U.S. Select Net Assets: $355m 1-Year Return: 33.74% Pharmaceuticals Index, composed of U.S. equities in the pharmaceuticals sector. The Fund uses a passive or Price: $177.65 3-Year Return: 7.84% indexing approach and invests by sampling the Index, Net Asset Value (NAV): $177.38 5-Year Return: 6.78% holding a collection of securities that approximates the full Index in key investment characteristics (such as Net Expense Ratio: 0.42% Yield: 1.23% market capitalization and industry weightings), fundamentals (such as return variability and yield), and As of: 03/31/2021 liquidity.
    [Show full text]
  • Next Generation Immuno-Oncology Targeting Hot and Cold Tumors
    Next generation immuno-oncology targeting hot and cold tumors March 2017 iTeos – General Disclaimer Company Presentation “This presentation has been prepared by iTeos and is furnished to you by iTeos on a confidential basis and solely for your information. This presentation contains forward-looking statements, including (without limitation) statements concerning the progress and expectations of our (pre-)clinical pipeline and the financials of the company. When used in this presentation, the words “anticipate,” “believe,” “can,” “could,” “estimate,” “expect,” “intend,” “is designed to,” “may,” “might,” “will,” “plan,” “potential,” “possible,” “predict,” “objective,” “should,” and similar expressions are intended to identify forward- looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors which might cause the actual results, financial condition, performance or achievements of iTeos, or industry results, to be materially different from any future results, financial conditions, performance or achievements expressed or implied by such forward-looking statements. All statements contained herein speak only as of the release date of this document. iTeos expressly disclaims any obligation to update any statement in this document to reflect any change or future development with respect thereto, any future results, or any change in events, conditions and/or circumstances on which any such statement is based, unless specifically required by law or regulation. Neither iTeos nor any of its officers,
    [Show full text]
  • IGNYTE-ESO: a Master Protocol to Assess Safety and Activity of Letetresgene Autoleucel (Lete-Cel; GSK3377794) Victoria L
    Sandra P. D’Angelo1, Jonathan Noujaim2, Fiona Thistlethwaite3, Albiruni R. Abdul Razak4, Silvia Stacchiotti5, Warren Chow6, John B.A.G. Haanen7, Anna Chalmers8, Steven I. Robinson9, Brian A. Van Tine10, Kristen N. Ganjoo11, Melissa L. Johnson12, 13 13 13 13 13 14 15 IGNYTE-ESO: a master protocol to assess safety and activity of letetresgene autoleucel (lete-cel; GSK3377794) Victoria L. Chiou , Thomas Faitg , Mary Woessner , Laura Pearce , Aiman Shalabi , Jean-Yves Blay , George D. Demetri 1Memorial Sloan Kettering Cancer Center, New York, NY, USA; 2Institut D’Hématologie-Oncologie, Hôpital Maisonneuve-Rosemont, Montreal, QC, Canada; 3The Christie NHS Foundation Trust and University of Manchester, Manchester, United Kingdom; 4Princess Margaret Cancer Centre and in HLA-A*02+ patients with synovial sarcoma or myxoid/round cell liposarcoma (Substudies 1 and 2) Mount Sinai Hospital, Toronto, ON, Canada; 5Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; 6City of Hope Comprehensive Cancer Center, Duarte, CA, United States; 7Antoni van Leeuwenhoek Ziekenhuis, Amsterdam, Netherlands; 8Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA; 9Mayo Clinic, Rochester, MN, USA; 10Washington University in St. Louis, St. Louis, MO, USA; 11Stanford University Medical Center, Stanford, CA, USA; 12Sarah Cannon Research Institute, Nashville, TN, USA; 13GlaxoSmithKline, Philadelphia, PA, USA; Poster No. TPS11582 14Centre Léon Bérard, Lyon, France; 15Dana-Farber Cancer Institute and Ludwig Center at Harvard, Boston, MA, USA Background Study design Study phases Unmet need IGNYTE-ESO (NCT03967223) is a master protocol that enables evaluation of multiple cell therapies Figure 3 displays the patient journey for both substudies, which includes leukapheresis for lete-cel manufacture, lymphodepletion chemotherapy, lete-cel infusion, and follow-up.
    [Show full text]